© Reuters. Gilead Sciences Inc pharmaceutical firm is seen through the outbreak of the coronavirus illness (COVID-19), in California
(Reuters) – Gilead Sciences Inc (NASDAQ:) posted a 26% rise in quarterly income that topped Wall Road estimates on Thursday, helped by gross sales of its antiviral drug, remdesivir, which is allowed to deal with COVID-19 sufferers the world over.
Remdesivir introduced in $1.9 billion within the fourth quarter ended Dec. 31, above analysts’ estimates of $1.34 billion, in keeping with Refinitiv IBES information.
Shares of Gilead have been up 2.5% in prolonged buying and selling.
The corporate forecast fiscal 2021 outcomes largely forward of analyst expectations and raised its dividend by 4.4%.
Fourth-quarter income totaled $7.42 billion, beating the typical analyst estimate of $7.33 billion.
Gilead projected fiscal 2021 product gross sales of $23.7 billion to $25.1 billion, forward of the Wall Road consensus of $24.27 billion in income, in keeping with IBES information from Refinitiv.
Fusion Media or anybody concerned with Fusion Media is not going to settle for any legal responsibility for loss or injury on account of reliance on the knowledge together with information, quotes, charts and purchase/promote indicators contained inside this web site. Please be absolutely knowledgeable relating to the dangers and prices related to buying and selling the monetary markets, it is likely one of the riskiest funding kinds attainable.